We’ve recently updated our valuation analysis.

Entera Bio Valuation

Is ENTX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

[object Object] Score

1/6

Valuation Score 1/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ENTX?

Other financial metrics that can be useful for relative valuation.

ENTX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue17.9x
Enterprise Value/EBITDA-0.4x
PEG Ration/a

Price to Book Ratio vs Peers

How does ENTX's PB Ratio compare to its peers?

The above table shows the PB ratio for ENTX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average0.8x
NRSN NeuroSense Therapeutics
2x0.09%US$19.8m
RUBY Rubius Therapeutics
0.5x58.0%US$19.2m
FBRX Forte Biosciences
0.5xn/aUS$21.0m
FWP Forward Pharma
0.3xn/aUS$20.9m
ENTX Entera Bio
1.3x16.2%US$19.3m

Price-To-Book vs Peers: ENTX is expensive based on its Price-To-Book Ratio (1.3x) compared to the peer average (0.8x).


Price to Earnings Ratio vs Industry

How does ENTX's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a9.2%
n/an/an/a

Price-To-Book vs Industry: ENTX is good value based on its Price-To-Book Ratio (1.3x) compared to the US Biotechs industry average (1.7x)


Price to Book Ratio vs Fair Ratio

What is ENTX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ENTX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.3x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ENTX's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of ENTX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ENTX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ENTX's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ENTX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.67
US$7.00
+944.6%
50.8%US$10.00US$2.00n/a3
Nov ’23US$0.76
US$8.33
+996.5%
20.4%US$10.00US$6.00n/a3
Oct ’23US$1.04
US$8.33
+701.3%
20.4%US$10.00US$6.00n/a3
Sep ’23US$1.35
US$7.50
+455.6%
20.0%US$9.00US$6.00n/a2
Aug ’23US$1.79
US$6.50
+263.1%
23.1%US$9.00US$5.00n/a4
Jul ’23US$1.38
US$6.75
+389.1%
19.2%US$9.00US$6.00n/a4
Jun ’23US$1.91
US$6.75
+253.4%
19.2%US$9.00US$6.00n/a4
May ’23US$2.45
US$6.75
+175.5%
19.2%US$9.00US$6.00n/a4
Apr ’23US$2.77
US$6.75
+143.7%
19.2%US$9.00US$6.00n/a4
Mar ’23US$2.18
US$8.00
+267.0%
35.4%US$12.00US$6.00n/a3
Feb ’23US$2.39
US$9.33
+290.5%
26.7%US$12.00US$6.00n/a3
Jan ’23US$2.82
US$11.00
+290.8%
7.4%US$12.00US$10.00n/a3
Dec ’22US$3.28
US$11.00
+235.4%
7.4%US$12.00US$10.00US$0.673
Nov ’22US$4.27
US$11.00
+157.6%
7.4%US$12.00US$10.00US$0.763
Oct ’22US$4.79
US$12.00
+150.5%
13.6%US$14.00US$10.00US$1.043
Sep ’22US$5.16
US$12.00
+132.6%
13.6%US$14.00US$10.00US$1.353
Aug ’22US$5.14
US$12.00
+133.5%
13.6%US$14.00US$10.00US$1.793
Jul ’22US$6.29
US$12.00
+90.8%
13.6%US$14.00US$10.00US$1.383
Jun ’22US$3.25
US$11.00
+238.5%
9.1%US$12.00US$10.00US$1.912
May ’22US$3.35
US$11.00
+228.4%
9.1%US$12.00US$10.00US$2.452
Apr ’22US$3.90
US$11.00
+182.1%
9.1%US$12.00US$10.00US$2.772
Mar ’22US$1.59
US$5.00
+214.5%
0%US$5.00US$5.00US$2.181
Feb ’22US$1.40
US$5.00
+257.1%
0%US$5.00US$5.00US$2.391
Jan ’22US$1.08
US$4.00
+270.4%
0%US$4.00US$4.00US$2.821
Dec ’21US$1.18
US$4.00
+238.7%
0%US$4.00US$4.00US$3.281

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies